Welcome to 2026 Analyst Day Matt Bacso VP, Investor Relations © 2026 PROCEPT BioRobotics Corporation. All Rights Reserved. 1 This presentation and the accompanying oral presentation also contain estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about performance and the future performance of the markets in which we compete are necessarily subject to a high degree of uncertainty and risk. Exchange Commission ("SEC"), including the Ann ...

Company Milestones and Financial Performance - PROCEPT BioRobotics achieved significant milestones, including Medicare reimbursement in 2021 and FDA clearance of the HYDROS System in 2023[12, 15] - The company's global revenue reached $224.5 million in 2024 and projects revenue guidance of $323 million[15, 18] - The company completed a $150 million equity follow-on and a $175 million equity follow-on[14, 15] HYDROS System and Market Penetration - The HYDROS Robotic System is resonating with all BPH hospital segments, driving market awareness[31, 34] - U.S. install base has shifted towards higher volume hospitals, with high-volume hospitals representing 61% of the install base in 1Q25, compared to 20% in 1Q23[30] - The company is on pace to become the 2 hospital-based resective BPH procedure in the U.S[18] Aquablation Therapy and Clinical Practice - Kansas City Urology & Oncology (KCUC) has increased annual BPH procedure volumes by 42% since 2021[56] - Dr Park's annual Aquablation procedures at KCUC doubled, demonstrating a 124% growth[58] - Aquablation therapy has increased surgical conversion rates from 10% to 25% due to more objective evaluation[62] Prostate Cancer and Aquablation Therapy - Approximately 26% of localized prostate cancer diagnoses are high risk, 50% are intermediate risk, and 24% are low risk[79] - Early data from PRCT001 + PRCT002 trials includes 88 prostate cancer patients treated, with 47 patients having 6-month follow-up data[125] - 70% of prostate cancer patients in PRCT001 + PRCT002 trials have intermediate-risk disease[127] - Single center data suggests Aquablation may delay cancer progression, with a 30% progression avoidance at 5 years compared to active surveillance[168]

Key Milestones & Financials - PROCEPT BioRobotics achieved global revenue of $224.5 million in 2024[15] - The company's revenue guidance for 2025 is $323 million[18] - In 2021, PROCEPT BioRobotics had an IPO at $1.2 billion market capitalization[12] HYDROS System & Commercial Update - HYDROS resonates with all BPH hospitals, with a 20% BPH hospital penetration rate[31] - The U.S. install base shows a shift from 1Q23 to 1Q25, with low-volume hospitals decreasing from 73% to 61%, medium-volume increasing from 6% to 8%, and high-volume increasing from 20% to 31%[30] Prostate Cancer & Aquablation Therapy - Approximately 60% of Active Surveillance patients will undergo radical treatment in 10-15 years[100] - In the U.S., 26% of localized prostate cancer diagnoses are high risk, 50% are intermediate risk, and 24% are low risk[79] - Early data from PRCT001 + PRCT002 trials includes 88 prostate cancer patients treated, with 65 having 3-month follow-up and 47 having 6-month follow-up[125] - 70% of prostate cancer patients in PRCT001 + PRCT002 have intermediate-risk disease[127] - 76% of patients in PRCT001 + PRCT002 have cancer in the Peripheral Zone[130]